Cullinan Therapeutics Stock Quote CGEM - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

19.10

Bid

19.00

Ask

19.03

Volume

667,559

18.38 Day's Range 19.81

7.64 52 Week Range 30.1886

Market Cap

1.054B

Previous Close

18.29

Open

18.38

Last Trade

1449

19.1

(formt)

Last Trade Time

Financial Volume

$ 12,747,816

VWAP

19.0962

Average Volume (3m)

909,296

Shares Outstanding

57,634,234

Dividend Yield

PE Ratio

-7.18

Earnings Per Share (EPS)

-2.66

Revenue

Net Profit

-153.16M

Cullinan Oncology Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. Cullinan Oncology Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.cullinantherapeutics.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Cullinan Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CGEM. The last closing price for Cullinan Therapeutics was $18.29. Over the last year, Cullinan Therapeutics shares have traded in a share price range of $ 7.64 to $ 30.1886.

Cullinan Therapeutics currently has 57,634,234 shares outstanding. The market capitalization of Cullinan Therapeutics is $1.05 billion. Cullinan Therapeutics has a price to earnings ratio (PE ratio) of -7.18.

Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024

Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such as...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	2.37	14.1661685595	16.73	19.81	16.58	912272	18.50083768	CS
4	1.62	9.26773455378	17.48	19.81	15.57	833911	17.29440342	CS
12	-6.52	-25.4488680718	25.62	30.1886	15.57	909296	21.58599921	CS
26	7.43	63.6675235647	11.67	30.1886	11.56	742927	20.023821	CS
52	8.64	82.6003824092	10.46	30.1886	7.64	466352	17.89932017	CS
156	-7.77	-28.9170078154	26.87	30.325	7.3	333790	15.7323843	CS
260	-22.9	-54.5238095238	42	59.85	7.3	325151	18.26734024	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
MIRAMIRA Pharmaceuticals Inc	$ 5.01 (627.35%)	158.15M
CMAXCareMax Inc	$ 5.19 (228.48%)	102.64M
NUKKNukkleus Inc	$ 0.499 (55.94%)	26.2M
SNOASonoma Pharmaceuticals Inc	$ 0.423 (37.34%)	4.88M
ONDSOndas Holdings Inc	$ 1.1297 (34.06%)	2.19M
LGCBLinkage Global Inc	$ 3.6601 (-29.82%)	168k
CGBSCrown LNG Holdings Ltd	$ 0.9997 (-29.10%)	3.39M
SPECSpectaire Holdings Inc	$ 0.3962 (-24.53%)	1.87M
GSUNGolden Sun Health Technology Group Ltd	$ 5.13 (-23.66%)	158.79k
PSNLPersonalis Inc	$ 2.9808 (-22.58%)	3.11M
NVDANVIDIA Corporation	$ 123.54 (4.76%)	239M
SQQQProShares UltraPro Short QQQ	$ 8.09 (-4.37%)	183.65M
MIRAMIRA Pharmaceuticals Inc	$ 5.01 (627.35%)	158.15M
SERVServe Robotics Inc	$ 8.73 (15.63%)	151.56M
NCPLNetcapital Inc	$ 0.1118 (7.50%)	124.37M